# Corporate Venture Capital Research Expansion.docx

# Strategic Capital Convergence: The Transformation of Animal Health and Agrifood Systems through Corporate Venture

## 1. Executive Intelligence: The Reordering of the Global Protein and Pet Care Economy

The global architecture of animal health, pet nutrition, and agrifood systems is currently undergoing its most significant structural realignment in decades. This transformation is not merely a function of incremental innovation but a fundamental reordering of value chains driven by the convergence of pharmaceutical precision, nutritional customization, and digital infrastructure. A comprehensive analysis of corporate venture capital (CVC) activity among the sector's dominant incumbents—Mars, Cargill, ADM, DSM-Firmenich, General Mills, and the major animal health pharmaceutical entities—reveals a unified strategic imperative: the transition from volume-based commodity models to outcome-based, capability-driven ecosystems.

The investment landscape, spanning the period from 2024 through early 2026, demonstrates a departure from traditional capacity expansion. Instead, capital is flowing aggressively into "Scope 3" sustainability solutions, digital diagnostics, and the "humanization" of animal wellness. Major agrifood conglomerates such as Cargill and ADM are effectively leveraging their venture arms to pivot from bulk commodity trading—historically a low-margin, high-volume business—toward high-margin precision nutrition and alternative protein biomanufacturing.1 This strategic drift allows these incumbents to hedge against the volatility of livestock markets and the existential threat of climate regulation.

Simultaneously, the consumer packaged goods (CPG) sector, exemplified by General Mills and Mars, is aggressively entering the pet supplement and veterinary health markets. This move is designed to offset stagnation in human food categories by capturing the high-growth "pet parent" demographic, which increasingly views companion animals as requiring medical and nutritional standards equivalent to humans.3 In the pharmaceutical domain, entities like Zoetis and Merck Animal Health are transitioning beyond simple therapeutics. Their venture activities indicate a strategy to view the animal not just as a biological entity but as a data node in a connected health network, investing heavily in AI-driven diagnostics and monitoring ecosystems.5

This report offers an exhaustive dissection of these corporate investment portfolios, analyzing the strategic rationales, specific asset capabilities, and the broader market implications of this capital deployment.

## 2. Mars Petcare: The "Walled Garden" Ecosystem Strategy

Mars Petcare distinguishes itself as the most vertically integrated investor in the pet care domain. Unlike competitors that may focus on isolated verticals—such as solely nutrition or therapeutics—Mars utilizes its dual-pronged venture apparatus, the Companion Fund and the Leap Venture Studio, to construct a comprehensive "walled garden" ecosystem. This strategy is designed to capture value at every conceivable touchpoint of a pet’s lifecycle, from genomic screening and microbiome analysis to nutrition, veterinary care, and end-of-life services.

### 2.1 The Companion Fund: Capitalizing on Deep Tech and Therapeutics

The Companion Fund, managed by Digitalis Ventures, serves as Mars' primary vehicle for high-stakes, deep-tech investments. The strategic evolution of this vehicle is evident in its capitalization trajectory; initially launched with $100 million, the fund tripled to $300 million for its second iteration (Companion Fund II).7 This expansion signals a deliberate shift toward growth-stage investing (Series B to D), enabling Mars to deploy check sizes between $10 million and $30 million.7 This capacity allows Mars to bridge the critical funding gap that often exists between early-stage venture risk and full corporate acquisition, effectively steering portfolio companies through their most capital-intensive growth phases.

#### 2.1.1 Therapeutic Innovation and Longevity

A central thesis of the Companion Fund is the treatment of aging as a manageable condition, extending the "healthspan" of companion animals. This focus on longevity is not merely altruistic but aligns with the economic imperative to extend the duration of the pet-owner relationship, thereby increasing the lifetime value (LTV) of the customer.

Rejuvenate Bio: This portfolio company represents the cutting edge of the fund's longevity thesis. Rejuvenate Bio is focused on gene therapies designed to treat age-related diseases.8 By targeting the underlying mechanisms of aging, Mars is positioning itself at the forefront of a potential paradigm shift where veterinary medicine moves from acute care to preventative genetic maintenance.

Gallant Therapeutics: Mars' investment in Gallant Therapeutics underscores a commitment to regenerative medicine. Gallant focuses on harnessing stem cell therapies to treat the root causes of disease rather than merely managing symptoms.8 This aligns with a broader industry trend toward biologics that offer curative potential for chronic conditions such as osteoarthritis.

PetMedix: Perhaps the most illustrative example of the complex competitive dynamics in this sector is PetMedix. Focused on developing fully speciated antibody-based therapeutics for companion animals, this company was incubated within the Mars ecosystem but was ultimately acquired by Zoetis, a pharmaceutical rival.8 This exit demonstrates the "frenemy" nature of the ecosystem, where Mars incubates technologies that advance the standard of care, even if the eventual commercialization rests with a pure-play pharmaceutical entity.

#### 2.1.2 Diagnostics and Infrastructure Democratization

The shortage of veterinary labor is a critical bottleneck in the industry. Mars addresses this through investments that leverage technology to amplify veterinary capacity.

Oncura: By enabling better access to veterinary imaging services through remote support and AI, Oncura addresses the severe shortage of veterinary radiologists.8 This technology allows general practitioners to capture diagnostic-quality images, which are then interpreted remotely. For Mars, which owns massive hospital networks like Banfield and VCA, this technology directly enhances the unit economics and diagnostic capabilities of its own clinics.

Scratchpay: Financial friction is a primary barrier to veterinary care access. Scratchpay provides simple payment solutions and financing.7 By investing in fintech solutions that help pet owners afford care, Mars indirectly ensures higher utilization rates for its veterinary services and higher compliance with expensive treatment plans.

#### 2.1.3 Next-Generation Nutrition and Direct-to-Consumer Models

The Companion Fund also targets nutritional innovation that challenges the traditional kibble model, acknowledging the consumer shift toward fresh and functional diets.

Smalls: As a direct-to-consumer (DTC) cat food brand, Smalls represents the "human-grade" fresh food segment.8 Mars' investment here acts as a hedge against the disruption of its legacy shelf-stable brands (like Whiskas or Royal Canin). It provides Mars with granular data on subscription economics and palatability in the high-growth fresh cat food category, a segment historically underserved compared to dog food.

Native Pet: This company focuses on functional nutrition—supplements that bridge the gap between food and medicine.8 As pet owners increasingly look to nutrition for preventative health (e.g., joint support, anxiety relief), investments in brands like Native Pet allow Mars to capture value in the high-margin supplement adjacency.

### 2.2 Leap Venture Studio: The High-Velocity Innovation Funnel

While the Companion Fund targets established, capital-intensive technologies, the Leap Venture Studio functions as a high-volume accelerator. A partnership with Michelson Found Animals and R/GA Ventures, Leap provides Mars with a "radar" for emerging trends in sustainability, alternative proteins, and digital services.11 The diverse cohorts of the Leap Venture Studio offer a microscopic view into the nascent innovations that may shape the future market.

#### 2.2.1 Advanced Diagnostics and Connected Health

The digitization of the pet is a recurring theme within the Leap portfolio, focusing on data acquisition outside the clinical setting.

Mella: This startup creates an ecosystem of wellness monitoring products, primarily smart thermometers that allow for non-invasive temperature monitoring.12 For Mars, integrating such hardware into the home allows for early detection of illness, driving timely veterinary visits and integrating with telehealth services.

AnimalBiome: Backed by both Mars and Cargill, AnimalBiome is a critical player in the microbiome space.12 The company provides microbiome restoration supplements and non-invasive diagnostics. This investment is strategic for Mars as it links directly to the "health through nutrition" thesis. Understanding the gut microbiome allows for the development of highly personalized prescription diets, a cornerstone of the Royal Canin business model.

Barkibu: An AI-powered pet health platform, Barkibu helps owners navigate care and understand pet health issues.12 This creates a digital front door to the veterinary system, using AI to triage cases and direct owners to appropriate care channels, optimizing patient flow.

Sniffspot: Operating as a marketplace for private dog parks, Sniffspot connects owners to safe outdoor spaces.12 While seemingly a lifestyle play, this platform addresses the needs of reactive dogs and urban pet owners, expanding the "pet-friendly" world and indirectly supporting dog ownership rates in dense urban environments.

#### 2.2.2 Sustainability and Alternative Proteins

Mars uses Leap to explore alternative supply chains that can decarbonize pet food production, a critical component of its Scope 3 emission reduction goals.

Wild Earth: A biotech startup developing pet food from fungi.12 This investment in non-animal protein sources is a direct hedge against the environmental impact and supply volatility of traditional meat proteins.

Jiminy’s: This company replaces traditional animal protein with cricket protein.12 Insect protein offers a highly sustainable, hypoallergenic alternative to beef or chicken, addressing both sustainability and the rising prevalence of food sensitivities in pets.

Project Blu: Focused on sustainable pet accessories, Project Blu leads the market in eco-friendly products, utilizing recycled materials.12 This reinforces the sustainability narrative surrounding pet ownership.

#### 2.2.3 Services and Pet Management Platforms

The "Service as a Software" (SaaS) model in pet care provides Mars with deep engagement channels.

Petcademy: Offering text-based training and behavioral support, Petcademy aims to reduce pet surrender rates.13 By addressing behavioral issues—a leading cause of pet relinquishment—Mars helps maintain the pet population, thereby preserving its customer base.

Dog Drop: A tech-enabled dog daycare with a subscription model.12 This investment taps into the "convenience economy" for millennial pet owners, blending physical care with digital booking interfaces.

BestyBnB: This platform provides safe temporary homes for pets during owner crises, such as domestic violence or medical emergencies.12 This "social impact" investment aligns with Mars' broader corporate responsibility goals while addressing a critical gap in the social safety net for pet owners.

## 3. Nestle Purina: The "Unleashed" Open Innovation Model

While Mars operates a closed ecosystem model, Nestle Purina has adopted a broad, open innovation strategy through its Unleashed accelerator. This program is designed to identify and support disruptive startups across Europe, the Middle East, and Asia-Pacific, functioning as a testbed for novel concepts without necessarily requiring immediate equity stakes or full integration. The Unleashed program allows Purina to "validate" technologies and business models through pilot programs funded by grants (typically CHF 50,000).14

### 3.1 Alternative Proteins and Sustainability

Purina’s Unleashed cohorts heavily feature startups addressing the protein crunch, mirroring the industry-wide anxiety regarding raw material sustainability.

MOA Foodtech: A Spanish startup combining biotechnology and AI to transform agrifood by-products into high-value, sustainable protein ingredients via fermentation.14 This technology offers a "circular economy" solution, turning waste into premium nutrition, which is highly attractive for a volume manufacturer like Purina seeking to lower its environmental footprint.

EniferBio: A Finnish biotech company using fungi fermentation to produce mycoprotein.14 Similar to Mars' bet on Wild Earth, Purina is exploring fungal proteins as a scalable, localized protein source that bypasses the complex logistics of the meat supply chain.

BlueNalu: Based in the USA, this startup focuses on cell-cultured seafood.15 As a major purchaser of fish for cat food, Purina has a vested interest in securing stable, mercury-free, and sustainable marine protein sources that do not deplete wild fish stocks.

### 3.2 Digital Platforms and Data Aggregation

Unleashed winners often focus on aggregating fragmented services, providing Purina with insight into consumer behavior beyond the food bowl.

Bookmypet: A UAE-based digital platform connecting pet parents with local service providers like groomers and boarders.16 This marketplace model provides data on service consumption patterns and pricing elasticity in emerging markets.

Dogami: A "petaverse" play involving a mobile game and non-fungible tokens (NFTs).16 While more experimental, this investment explores gamification and brand engagement in virtual spaces, targeting a younger demographic of future pet owners.

BorrowMyDoggy: A UK-based community platform connecting dog owners with local borrowers for walks.15 This service lowers the barrier to dog interaction and ownership, potentially expanding the market by allowing non-owners to experience pet companionship.

### 3.3 Veterinary Technologies

Vetwork: An Egyptian startup providing an Uber-like service for veterinary care at home.14 This model addresses the "last mile" of veterinary delivery, offering convenience and reducing stress for pets.

Bioceltix: Focused on stem cell therapies for companion animals.

Feragen: An Austrian genetic testing company.14 Like Mars' Wisdom Panel and Zoetis' Basepaws, Purina recognizes that genetic data is the foundational layer for personalized nutrition.

## 4. General Mills (301 INC & Gold Medal Ventures): The Humanization of Pet Wellness

General Mills has aggressively pivoted toward the pet sector, a move necessitated by the slowing growth of traditional human cereal and processed food categories. Following its blockbuster acquisition of Blue Buffalo, the company is using its venture arm, 301 INC, and the Gold Medal Ventures growth fund to diversify into high-growth pet segments, specifically supplements and "humanized" feeding solutions.3

### 4.1 The Strategic Pivot to Pet Supplements

The acquisition of Fera Pets, Inc. marks a decisive entry into the pet supplement category. Fera Pets fits the "vet-founded, science-backed" criteria that modern consumers demand.3

Economic Rationale: The "treat" category is saturated, but "functional supplements" (targeting hip & joint, anxiety, skin & coat) offer pharmaceutical-like margins with food-like regulatory pathways. By acquiring Fera Pets through its growth equity fund, General Mills is acknowledging that future growth lies in the "medicine cabinet" rather than the pantry.4

Operational Integration: Fera Pets is housed under the growth equity fund to incubate and scale before potential full integration into the core Blue Buffalo portfolio.4 This structure allows the brand to maintain its "indie" credibility—a crucial factor for millennial pet owners who are skeptical of "Big Pet Food"—while leveraging General Mills' massive supply chain and distribution leverage.

### 4.2 Home Cooking and the "Childless" Demographic

General Mills is astute in recognizing demographic shifts that influence feeding behaviors.

Dog Child: This investment targets the "home cooking" demographic.18 Rather than fighting the trend of owners cooking for pets (which reduces commercial kibble sales), Dog Child offers meal mixes to ensure nutritional completeness. This allows General Mills to monetize the home-cooking trend rather than lose market share to it.

Sociological Context: Research indicates that high investment in dog ownership often mirrors parental investment in children, particularly among childless owners.19 Brands like Dog Child and Smalls cater specifically to this psychographic, offering products that mimic the visual and nutritional cues of human meal preparation.

### 4.3 High-Protein and Activity Monitoring

Smalls: General Mills, parallel to Mars, has invested in Smalls.18 This concurrent backing by two massive competitors validates the high-protein, human-grade cat food segment as a permanent market shift rather than a niche fad.

PitPat: An investment in dog activity monitoring.18 This provides General Mills with behavioral data, potentially allowing for the creation of activity-based feeding recommendations for their food brands, closing the loop between caloric intake and expenditure.

## 5. Cargill: The "Barbell" Strategy of Upstream Innovation

Cargill’s venture strategy is distinct from the CPG-focused approaches of Mars or General Mills. As an upstream agribusiness, its venture activities focus on micronutrition, alternative protein inputs, and digestive health. Cargill employs a "barbell strategy," balancing futuristic bets on cell-cultured meat with robust, cash-generating physical infrastructure acquisitions.

### 5.1 The Alternative Protein Hedge

Cargill is systematically hedging against the volatility of traditional livestock markets through significant bets on cultivated meat and fermentation technologies.

Cultivated Meat: Cargill participated in the Series A investment of Aleph Farms (Israel), a company growing steaks from bovine cells, and was an early investor in Memphis Meats (now Upside Foods).20 These investments allow Cargill to remain the primary protein supplier even if the mechanism of production shifts from the farm to the bioreactor.

Mycoprotein and Fermentation:

ENOUGH (formerly 3F Bio): Cargill invested in and partnered with ENOUGH to produce ABUNDA mycoprotein using sustainable grain fermentation.22 The co-location of ENOUGH’s facility with Cargill’s plant in Sas van Gent, Netherlands, demonstrates a strategy of industrial symbiosis—Cargill provides the feedstock (glucose syrup) and infrastructure, and ENOUGH produces the protein.

CUBIQ Foods: Cargill partnered with this food-tech company to access novel fat technologies (like Go!Drop) that improve the flavor and texture of plant-based foods.23 This addresses the sensory gap that often limits the adoption of alternative proteins.

### 5.2 Animal Nutrition and the "Postbiotic" Era

Cargill has moved aggressively into the "health through nutrition" space, moving beyond basic calories to functional ingredients that modulate the animal's biology.

Micronutrition Expansion: The acquisitions of Diamond V (fermentation postbiotics) and Delacon (phytogenics) form the backbone of Cargill’s "Micronutrition & Health Solutions" business. In late 2025, Cargill expanded its Engerwitzdorf, Austria facility by 50% to meet demand for these solutions.24 This indicates a strategic shift from selling "feed" to selling "immune support" and "gut health."

AnimalBiome: Cargill’s investment in AnimalBiome (alongside Mars) underscores the industry-wide obsession with gut health.25 For Cargill, understanding the microbiome is essential to validating and selling its portfolio of prebiotics, probiotics, and postbiotics.

### 5.3 Infrastructure Consolidation

While exploring high-tech ventures, Cargill continues to consolidate traditional assets to secure its distribution network. The 2024 acquisition of two feed mills from Compana Pet Brands (in Denver and Kansas City) strengthens its manufacturing footprint for the ag-retail and lifestyle farming segments.26 This ensures that Cargill retains the physical capacity to serve the "backyard" market, which requires different logistics than large-scale commercial integrators.

## 6. ADM (Archer Daniels Midland): The Biomanufacturing Backend

ADM’s venture arm, ADM Ventures, focuses heavily on the intersection of human and animal nutrition, leveraging its massive fermentation capacities. ADM positions itself as the "manufacturing backend" for the biotech revolution in food, effectively selling the "picks and shovels" for the alternative protein gold rush.

### 6.1 Precision Fermentation and Alternative Proteins

ADM Ventures invests in startups that require scaling industrial fermentation—a core ADM competency.

Bond Pet Foods: ADM invested in Bond, which creates nature-identical meat proteins (like chicken protein) via precision fermentation using yeast, eliminating the need for animal slaughter.27 This technology addresses the supply shortage of high-quality animal proteins and sustainability concerns.

Air Protein: An investment in creating protein from CO2, a technology with massive potential implications for decoupling feed production from arable land use.27

Nourished: This investment in 3D-printed personalized nutrition showcases ADM's interest in the ultimate customization of nutrient delivery.27

### 6.2 The ADM-Alltech Joint Venture: A Structural Shift

In a major consolidation move announced in late 2025 (launching Q1 2026), ADM and Alltech agreed to form a North American animal feed joint venture.28

Structural Details: Alltech contributes its Hubbard Feeds and Masterfeeds businesses (comprising 32 mills), while ADM contributes 11 mills. Alltech holds the majority ownership stake.28

Strategic Implications: This joint venture allows ADM to offload the operational complexity and lower margins of commodity feed milling while retaining an outlet for its high-value ingredients. It signals ADM's strategic desire to move up the value chain toward premixes, enzymes, and bioactive compounds, leaving the bulk feed mixing to Alltech, a specialist in that domain.

### 6.3 Microbiome and Pet Nutrition Focus

ADM aggressively markets its research capabilities, touting "40+ University Partnerships" and "13 Applied Research Centers" to develop pet nutrition solutions.1 Their proprietary products, such as Protexin Veterinary and DermalEase (award winners), highlight a focus on skin and coat health via probiotic and enzymatic pathways.1 This reinforces the trend of "functionalizing" pet food ingredients to treat specific clinical indications.

## 7. DSM-Firmenich: Restructuring for Precision and Sustainability

Following the merger of DSM and Firmenich, the entity is in a state of strategic realignment regarding its Animal Nutrition & Health (ANH) business. In 2024, DSM-Firmenich announced plans to separate or spin off the ANH unit to reduce exposure to vitamin price volatility.30 However, its venture and innovation activities remain robust and highly targeted.

### 7.1 Deep Science Ventures

Despite the restructuring, DSM’s venture portfolio remains a powerhouse of deep science in nutrition and sustainability.

Veramaris: A joint venture (initially with Evonik) producing algal Omega-3 (EPA/DHA) for aquaculture and pet food.31 This innovation is critical for reducing the aquaculture industry's reliance on wild-caught fish oil, addressing a major sustainability bottleneck.

Bovaer: While an internal development, the commercialization of Bovaer, a feed additive that significantly reduces methane emissions in ruminants, is a cornerstone of DSM's sustainability offering. This product aligns with venture investments in companies like Athian (a carbon marketplace for livestock), creating a mechanism to monetize the carbon reductions achieved by using DSM products.32

Animal Microbiome Analytics: DSM holds an equity interest in this company.32 The fact that DSM, Mars, and Cargill all hold stakes in microbiome analytics confirms that the industry views gut health data as the next critical frontier in animal performance and health.

### 7.2 Next-Generation Premix Manufacturing

DSM-Firmenich launched a "next-generation" pet-only premix facility in Tonganoxie, Kansas, in October 2025.33 This facility features fully automated micro-ingredient addition, addressing the critical industry pain point of safety and traceability. This investment demonstrates that while DSM may be spinning off commodity vitamins, it is doubling down on high-value, safe, and precise premix solutions for the premium pet food market, where safety recalls can be catastrophic for brands.

## 8. Pharmaceutical CVCs: The Shift from Therapeutics to Data Ecosystems

The major animal health pharmaceutical companies—Zoetis, Merck, and Elanco—have shifted their venture focus from developing new chemical entities (NCEs) to acquiring technology, data, and diagnostics. They are transforming from drug manufacturers into holistic health partners that embed themselves into the veterinary workflow.

### 8.1 Zoetis: The "Continuum of Care" via Acquisition

Zoetis uses its balance sheet to acquire successful startups, often those incubated by other VCs (like Mars' Companion Fund). Their strategy is to own the diagnostic trigger that leads to the therapeutic sale.

Genetics & Diagnostics:

Basepaws: Acquired in 2022, Basepaws provides genetic testing for cats.34 This acquisition gives Zoetis a massive genomic database to fuel future R&D and create personalized medical insights, expanding their precision medicine capabilities.

Techcyte: Zoetis led a $21 million round in Techcyte, an AI-based digital pathology platform.6 This technology powers Zoetis's Vetscan Imagyst, allowing clinics to scan samples and get AI-driven results in minutes. This effectively decentralizes the reference lab, keeping revenue within the clinic and accelerating the time-to-treatment (often with Zoetis drugs).

Therapeutics:

PetMedix: Acquired in 2023, PetMedix develops species-specific monoclonal antibodies.9 This acquisition cements Zoetis's leadership in the lucrative dermatology and pain antibody market, complementing its existing blockbusters like Cytopoint and Librela.

Adivo: Another acquisition in the antibody space, further fortifying the pipeline.9

Quality of Life Measurement:

NewMetrica: Acquired in 2022, NewMetrica develops tools to scientifically measure animal quality of life.9 This provides a quantitative metric for pain and well-being, crucial for proving the efficacy of pain management therapies.

### 8.2 Merck Animal Health (MSD): Intelligence and Aquaculture

Merck Animal Health Ventures focuses heavily on data tagging ("smart animal" tech) and consolidating the aquaculture sector.

Smart Monitoring Investments:

Vedi: A universal health record platform for pets (Seed investment).36 This aims to solve the fragmentation of veterinary records.

LeeO: Focusing on individual pig monitoring and traceability.36

TARGAN: Automated poultry vaccination and sexing systems.36 This technology automates high-volume hatchery tasks, improving efficiency and animal welfare.

Aquaculture Dominance: Merck acquired Elanco’s aqua business for $1.3 billion in 2024.37 This consolidation makes Merck a dominant player in warm water and salmonid aquaculture health, combining vaccines, anti-parasitics, and water treatment into a comprehensive portfolio.

### 8.3 Elanco: The Venture Builder Model

Elanco has adopted a unique strategy by partnering with Alloy Partners to launch the OneHealth Studio in Indianapolis.38

Venture Studio Strategy: Unlike a traditional CVC that invests in existing companies, Elanco is building companies from scratch to fill specific gaps in its pipeline or the broader market. The studio creates startups at the intersection of animal, plant, and human health.40

Focus Areas: The studio targets diagnostics, microbiome research, and antimicrobial resistance (AMR).41

Therapeutics: Elanco is heavily investing in next-generation immuno-therapeutics (monoclonal antibodies) for dermatology (launching Befrena) and parvovirus.42

## 9. Phibro Animal Health: The Contrarian Consolidator

While Zoetis and Elanco divest older portfolios to focus on biotech and data, Phibro Animal Health acts as a consolidator of mature assets, betting on the continued necessity of conventional production tools.

The Zoetis MFA Acquisition: In 2024, Phibro acquired Zoetis’s Medicated Feed Additive (MFA) product portfolio for $350 million.43

Strategic Rationale: While "medicated feed" (antibiotics/ionophores) is falling out of favor in consumer-facing markets due to "No Antibiotics Ever" trends, it remains a vital tool for global protein production efficiency. Phibro is betting that these assets will remain cash cows in specific geographies and production systems, allowing them to dominate a segment that larger pharma players are exiting for ESG reasons.

Diversification: Phibro is also investing in nutritional specialty products and vaccines (including aquaculture via the acquisition of KoVax technology) to balance its portfolio.45

## 10. Boehringer Ingelheim Venture Fund (BIVF): Groundbreaking Science

Boehringer Ingelheim’s venture arm (BIVF) operates with a mandate to invest in "groundbreaking science," often looking at platforms with cross-species potential.

Pawru: An investment in a digital platform connected to the pet ecosystem.47

Saiba Animal Health: The acquisition of Saiba adds a novel vaccine platform to their portfolio, focusing on treating chronic diseases (like allergies or pain) with vaccines rather than daily pills.48

Strategic Focus: BIVF invests heavily in regenerative medicine, oncology, and digital health, often backing companies that can pivot technology from human to animal health applications.49

## 11. Synthesis and Future Outlook

The investment behaviors of Mars, Cargill, ADM, General Mills, and the pharma majors paint a clear picture of the industry's trajectory.

Table 3: Strategic Capital Focus Matrix

Conclusion:

The industry is moving from a model of inputs (selling feed, selling drugs) to a model of outcomes (selling health, selling sustainability).

The Ecosystem War: Mars has successfully built a platform where they own the food, the hospital, the lab, and the insurance. Competitors like General Mills must rely on strong CPG branding and niche acquisitions (Fera Pets) to compete without that infrastructure.

The End of Commodity Ingredients: Cargill and ADM are signaling the end of the commodity era. By investing heavily in fermentation and cell culture, they are preparing for a future where protein is brewed, not raised.

Data as the New Blockbuster: For Zoetis and Merck, the next "blockbuster drug" isn't a molecule; it's a diagnostic platform (Techcyte, Basepaws) that locks clinics into their ecosystem and dictates the treatment protocol.

Value creation in animal health and agrifood has definitively migrated from volume to precision. The winners of the next decade will be those who can successfully integrate these disparate technologies—genomic insights, alternative proteins, and AI diagnostics—into cohesive solutions for farmers and pet owners.

Report generated by Expert Industry Analyst

Date: January 2026

#### Works cited

Pet Nutrition | Pet Product Manufacturing - ADM, accessed on January 13, 2026, https://www.adm.com/en-us/products-services/pet-nutrition/

Cargill Animal Nutrition | Livestock Feed & Fish Feed, accessed on January 13, 2026, https://www.cargill.com/animal-nutrition

General Mills Acquires Fera Pets, Inc., Introduces Growth Fund, accessed on January 13, 2026, https://investors.generalmills.com/press-releases/press-release-details/2023/General-Mills-Acquires-Fera-Pets-Inc.-Introduces-Growth-Fund/default.aspx

General Mills enters pet supplement space with Fera Pets acquisition | PetfoodIndustry, accessed on January 13, 2026, https://www.petfoodindustry.com/pet-food-market/market-trends-and-reports/article/15638419/general-mills-enters-pet-supplement-space-with-fera-pets-acquisition

Merck Animal Health Ventures, accessed on January 13, 2026, https://www.merck-animal-health.com/animal-health-ventures/

Techcyte Closes $21 Million Funding Round, accessed on January 13, 2026, https://techcyte.com/techcyte-closes-21-million-funding-round/

Mars Companion Fund to take bigger bets on petcare startups - - Global Corporate Venturing, accessed on January 13, 2026, https://globalventuring.com/corporate/consumer/mars-companion-fund-interview/

Animal Health - Digitalis Ventures, accessed on January 13, 2026, https://companionfund.com/

Zoetis - 2026 Company Profile, Funding, Competitors & Financials - Tracxn, accessed on January 13, 2026, https://tracxn.com/d/companies/zoetis/__SbLzlTxYiSlmz3XagzXTMsR3piY3CHVN6dp8R2Zz6hE

15 Best Pet Tech Investors Bankrolling Pet Startups in 2026 - Ellty, accessed on January 13, 2026, https://www.ellty.com/blog/pet-tech-investors

Six Innovative Pet Care Startups Join Leap's Cohort 7 - Michelson Impact Ventures, accessed on January 13, 2026, https://www.michelson.vc/leaps-cohort-seven-is-revolutionizing-the-way-we-care-for-our-furry-friends/

Startup Portfolio | Leap Venture Studio, accessed on January 13, 2026, https://www.leapventurestudio.com/portfolio

Leap Venture Studio Launches Ninth Cohort of Annual Accelerator Program for Pet-Care Startups - Michelson Found Animals, accessed on January 13, 2026, https://www.foundanimals.org/leap-venture-studio-launches-ninth-cohort-of-annual-accelerator-program-for-pet-care-startups/

Europe's most innovative pet-care start-ups with 300,000 CHF accelerator fund | Purina EU, accessed on January 13, 2026, https://www.purina.eu/latest-news/articles/news-communities/europes-most-innovative-pet-care-start-ups-300000-chf

Nestlé Purina PetCare announces the six winners of the UNLEASHED Accelerator Lab programme 2021, accessed on January 13, 2026, https://www.unleashedbypurina.com/press-releases/nestle-purina-petcare-announces-the-six-winners-of-the-unleashed-accelerator-lab-programme-2021

These are the winners of Purina's Unleashed 2023 - GlobalPETS, accessed on January 13, 2026, https://globalpetindustry.com/news/these-are-winners-purinas-unleashed-2023/

301 Inc, accessed on January 13, 2026, https://www.301inc.com/

General Mills acquires pet health brand Fera Pets - Feed & Additive Magazine, accessed on January 13, 2026, https://www.feedandadditive.com/general-mills-acquires-pet-health-brand-fera-pets/

Redefining Parenting and Family – The Child-Like Role of Dogs in Western Societies | European Psychologist - Hogrefe eContent, accessed on January 13, 2026, https://econtent.hogrefe.com/doi/10.1027/1016-9040/a000552

Cargill invests in cultured meat company Aleph Farms, accessed on January 13, 2026, https://www.cargill.com/2019/cargill-invests-in-cultured-meat-company-aleph-farms

Protein innovation: Cargill invests in cultured protein, accessed on January 13, 2026, https://www.cargill.com/story/protein-innovation-cargill-invests-in-cultured-meats

Cargill and ENOUGH expand partnership to provide consumers with innovative, sustainable protein options, accessed on January 13, 2026, https://www.cargill.com/2024/cargill-and-enough-expand-partnership-to-provide-consumers

Cargill partners with CUBIQ FOODS to bring innovative fats to plant-based food, accessed on January 13, 2026, https://www.cargill.com/story/a-big-fat-solution-cargill-partners-with-cubiq-foods-to-bring

Cargill Animal Nutrition & Health Increases Micronutrition Production Capacity to Meet Growing Customer Demand, accessed on January 13, 2026, https://www.cargill.com/2025/cargill-animal-nutrition-health-increases-micronutrition

Cargill invests in AnimalBiome pet gut health company | PetfoodIndustry, accessed on January 13, 2026, https://www.petfoodindustry.com/news-newsletters/pet-food-news/article/15468047/cargill-invests-in-animalbiome-pet-gut-health-company

Cargill acquires two US feed mills, strengthens production and distribution capabilities to grow with customers, accessed on January 13, 2026, https://www.cargill.com/2024/cargill-acquires-two-us-feed-mills-strengthens-production

ADM Ventures investment portfolio | PitchBook, accessed on January 13, 2026, https://pitchbook.com/profiles/investor/234071-83

ADM, Alltech to bring together unparalleled expertise and experience in new North American animal feed joint venture, accessed on January 13, 2026, https://www.alltech.com/press-release/adm-alltech-to-bring-together-unparalleled-expertise-and-experience-in-new-north-american-animal-feed-joint-venture

ADM-Alltech-to-Bring-Together-Unparalleled-Expertise-and-Experience-in-New-North-American-Animal-Feed-Joint-Venture, accessed on January 13, 2026, https://www.adm.com/en-us/news/news-releases/2025/9/adm-alltech-to-bring-together-unparalleled-expertise-and-experience-in-new-north-american-animal-feed-joint-venture/

dsm-firmenich to separate out Animal Nutrition & Health business from the Group, accessed on January 13, 2026, https://www.prnewswire.co.uk/news-releases/regulatory-news/dsm-firmenich-to-separate-out-animal-nutrition--health-business-from-the-group-302062325.html

Pet nutrition insights from Fi Europe 2024: dsm-firmenich, accessed on January 13, 2026, https://www.dsm-firmenich.com/en/businesses/taste-texture-health/news-events/articles/pets/pet-nutrition-insights-from-fi-europe-2024-dsm-firmenich.html

List of equity interests DSM B.V., accessed on January 13, 2026, https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/corporate-governance/list-of-equity-interests-dsm-bv-31122024.pdf

dsm-firmenich launches next generation, fully automated pet-only premix facility in Tonganoxie, Kansas, accessed on January 13, 2026, https://www.dsm-firmenich.com/en/businesses/taste-texture-health/news-events/press-releases/dsm-firmenich-launches-next-generation-fully-automated-pet-only-premix-facility-in-tonganoxie-kansas.html

Animal Attraction: Basepaws Acquired by Zoetis - Gingerbread Capital, accessed on January 13, 2026, https://gingerbreadcap.com/2022/09/gingerbreadcaps-hot-summer-2022/

Zoetis Announces Agreement to Acquire Basepaws, an Innovative Leader in Petcare Genetics, to Strengthen its Portfolio of Precision Animal Health Solutions, accessed on January 13, 2026, https://investor.zoetis.com/news/news-details/2022/Zoetis-Announces-Agreement-to-Acquire-Basepaws-an-Innovative-Leader-in-Petcare-Genetics-to-Strengthen-its-Portfolio-of-Precision-Animal-Health-Solutions/default.aspx

List of Investments by Merck Animal Health (Oct, 2025) - Tracxn, accessed on January 13, 2026, https://tracxn.com/d/corporate-investments/investments-by-merck-animal-health/__fZedknsrdLDooADJZ8PpX9365nXuD59HL8nryFAdBjE

Merck Animal Health to Acquire Elanco's Aqua Business, accessed on January 13, 2026, https://www.merck.com/news/merck-animal-health-to-acquire-elancos-aqua-business/

Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health - PR Newswire, accessed on January 13, 2026, https://www.prnewswire.com/news-releases/alloy-partners-launches-onehealth-studio-to-create-startups-at-the-convergence-of-animal-plant-and-human-health-302613830.html

Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health, accessed on January 13, 2026, https://www.alloypartners.com/articles/onehealth-studio-launch

Elanco Animal Health and Alloy Partners Launch OneHealth Venture Studio - Tiger Brokers, accessed on January 13, 2026, https://www.itiger.com/news/2583988395

Innovation - Elanco, accessed on January 13, 2026, https://www.elanco.com/us/innovation

Elanco Announces Investment in U.S. Manufacturing and R&D, accessed on January 13, 2026, https://www.elanco.com/us/newsroom/featured-articles/announces-investments-in-us

Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products, accessed on January 13, 2026, https://investors.pahc.com/press-releases/press-release-details/2024/Phibro-Animal-Health-Corporation-Completes-Acquisition-of-Zoetis-Medicated-Feed-Additive-Product-Portfolio-and-Certain-Water-Soluble-Products/default.aspx

Zoetis to Sell Medicated Feed Additive Portfolio to Phibro Animal Health, accessed on January 13, 2026, https://investors.pahc.com/press-releases/press-release-details/2024/Zoetis-to-Sell-Medicated-Feed-Additive-Portfolio-to-Phibro-Animal-Health/default.aspx

History - PAHC - Phibro Animal Health Corporation, accessed on January 13, 2026, https://www.pahc.com/about-us/history/

Phibro Animal Health Invests in Animal Nutrition Industry - Omaha, Nebraska, Facility Expansion - PAHC, accessed on January 13, 2026, https://www.pahc.com/phibro-animal-health-invests-in-animal-nutrition-industry-omaha-nebraska-facility-expansion/

Boehringer Ingelheim US Subsidiaries and Affiliate Companies, accessed on January 13, 2026, https://www.boehringer-ingelheim.com/us/about-us/boehringer-ingelheim-subsidiaries-and-affiliate-companies

Partnering for future innovation in animal health - Boehringer Ingelheim, accessed on January 13, 2026, https://www.boehringer-ingelheim.com/us/partnering/animal-health-partnering

Our portfolio | Venture Fund | Boehringer Ingelheim, accessed on January 13, 2026, https://www.boehringer-ingelheim-venture.com/portfolio